Skip to Content

Reolysin Approval Status

Reolysin (pelareorep) is a proprietary formulation of the human reovirus (Respiratory Enteric Orphan Virus) in development for the treatment of various cancers and cell proliferative disorders.

Development Status and FDA Approval Process for Reolysin

DateArticle
Apr 17, 2015Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Designation from the FDA for Malignant Gliomas
Feb 17, 2015Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Designation from FDA for Reolysin for Pancreatic Cancer
Feb 11, 2015Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Designation from FDA for Reolysin for Ovarian Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide